Key Points
- Director Francesco Bianchi sold 3,500 LivaNova shares at an average price of $78.01, generating $273,035 and reducing his position by 44.11% to 4,434 shares. He also sold 1,650 shares on August 31.
- LivaNova recently exceeded quarterly expectations, reporting $1.26 in earnings per share versus the $1.09 consensus and revenue of $390.59 million, up 10.8% year over year.
- Analyst sentiment remains favorable, with six Buy ratings and five Holds producing a “Moderate Buy” consensus and an average price target of $84.12; institutional investors own 97.64% of the stock.
LivaNova PLC (NASDAQ:LIVN - Get Free Report) Director Francesco Bianchi sold 3,500 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the sale, the director owned 4,434 shares in the company, valued at approximately $345,896.34. This trade represents a 44.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Francesco Bianchi also recently made the following trade(s):
- On Monday, August 31st, Francesco Bianchi sold 1,650 shares of LivaNova stock. The shares were sold at an average price of $79.72, for a total value of $131,538.00.
LivaNova Stock Performance
Shares of LivaNova stock opened at $80.63 on Tuesday. LivaNova PLC has a one year low of $48.82 and a one year high of $85.76. The company has a market cap of $4.44 billion, a PE ratio of 23.86 and a beta of 0.87. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. The business has a 50-day simple moving average of $80.28 and a 200-day simple moving average of $73.44.
LivaNova (NASDAQ:LIVN - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.17. The firm had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business's quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.05 earnings per share. On average, equities research analysts forecast that LivaNova PLC will post 3.77 EPS for the current fiscal year.
Institutional Trading of LivaNova
Institutional investors have recently modified their holdings of the stock. Allworth Financial LP boosted its holdings in shares of LivaNova by 93.5% in the 2nd quarter. Allworth Financial LP now owns 298 shares of the company's stock valued at $25,000 after buying an additional 144 shares in the last quarter. Hantz Financial Services Inc. grew its position in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company's stock valued at $27,000 after buying an additional 267 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in LivaNova during the 2nd quarter worth $37,000. Covestor Ltd raised its stake in LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company's stock worth $46,000 after acquiring an additional 392 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in LivaNova by 63.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 797 shares of the company's stock valued at $49,000 after acquiring an additional 308 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently commented on the stock. Mizuho boosted their target price on shares of LivaNova from $90.00 to $95.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. Zacks Research cut LivaNova from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. Weiss Ratings raised LivaNova from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, August 18th. Stifel Nicolaus set a $85.00 price target on LivaNova in a report on Wednesday, August 5th. Finally, Freedom Capital raised LivaNova to a "hold" rating in a research report on Tuesday, June 30th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, LivaNova has a consensus rating of "Moderate Buy" and a consensus price target of $84.12.
Read Our Latest Research Report on LivaNova
LivaNova Company Profile
(
Get Free Report)
LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.
LivaNova's Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
